Arrhythmias, Cardiac, Diabetes type1, Hypoglycemia
Conditions
Brief summary
The investigators hypothesise that following episodes of hypoglycemia, rebound hyperglycemia may result in a prolonged period of increased QTc and, thereby, increased susceptibility to serious cardiac arrhythmias in patients with type - 1 diabetes.
Detailed description
In this study, changes in cardiac rhythm, haemodynamic regulation, and hormonal response will be evaluated during insulin-induced hypoglycemia followed by hyperglycemia and euglycemia, respectively, on two separate experimental days. Twenty-four patients with type-1 diabetes are included. Patients are randomised 1:1 to start with either the combined hypo- and hyperglycemic or the hypo- and euglycemic clamp. After an overnight 10 hour fast, participants are admitted for a 255 minute clamp. An individualised insulin infusion will be initiated targeting a plasma glucose level of 5.0-8.0 mmol/l. When the targeted plasma glucose level is achieved, the hyperinsulinemic euglycemic clamp will be initiated at time 0. The insulin infusion will be fixed at an infusion rate 80 mU/m2/min and a 20% glucose infusion will be initiated in order to regulate plasma glucose levels. After 45 min of monitoring at euglycemic plasma glucose level, plasma glucose will be decreased over a period of 30 minutes, targeting 2.5 mmol/l for a period of 60 min in a hyperinsulinemic hypoglycemic clamp. From 135 min to 195 min, plasma glucose levels will be increased to either hyperglycemic level or euglycemic level and will be kept constant for 105 minutes. Echocardiography is performed at baseline, at hypoglycemic level and at hyper-or normoglycemic level. Blood samples are taken every 15 minutes throughout the entire clamp, however bedside plasma glucose is analysed every fifth minute. A Holter-ECG is obtained throughout the entire clamp.
Interventions
OTHERHypoglycemic combined with either normo or hyperglycemic clamp.
Twenty-four patients with type 1 diabetes has been recruited for a cross-over study including two experimental days, a combined hypo- and hyperglyemic clamp and a combined hypo- and euglycemic clamp, respectively. Patients will be randomised 1:1 to start with either the combined hypo- and hyperglycemic or the hypo- and euglycemic clamp. The hypo- and hyperglycemic or the hypo- and euglycemic clamp are estimated to last 255 minutes. The two clamp days will be separated by at least 30 days.
Sponsors
University Hospital, Gentofte, Copenhagen
Hillerod Hospital, Denmark
Steno Diabetes Center Copenhagen
Study design
Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Informed and written consent * Type 1 diabetes diagnosed according to the criteria of the World Health Organization (WHO) * Age 18-70 years * Insulin treatment for ≥3 years
Exclusion criteria
* Arrhythmia diagnosed prior to the screening visit * Implantable cardioverter defibrillator (ICD) or pacemaker at the time of inclusion * Severe heart failure (left ventricular ejection fraction \<25%) * Structural heart disease (Wolf-Parkinson-White syndrome, congenital heart disease, severe valve disease) * Thyroid dysfunction (except for well-regulated eltroxin substituted myxoedema) * Anemia (male: hemoglobin \<8.0; female: hemoglobin \<7.0 mmol/l)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| QTc prolongation. | 255 minutes | Difference in mean corrected QT interval (QTc) prolongation during hyperglycemia compared to euglycemia both preceded by insulin induced hypoglycemia |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Atrial ectopic beats. | 255 minutes | Difference in atrial ectopic beats (prematurity threshold 30%),during hyperglycemia compared to euglycemia both preceded by insulin-induced hypoglycemia |
| Bradycardia | 255 minutes | Difference in non-clinically significant bradycardia (≤45 bpm for 5 seconds) during hyperglycemia compared to euglycemia both preceded by insulin-induced hypoglycemia |
| Ventricular premature beats | 255 minutes | Difference in ventricular premature beats during hyperglycaemia compared to euglycaemia both preceded by insulin-induced hypoglycaemia |
| Glucagon response | 255 minutes | Differences in glucagon response during hyperglycemia compared to euglycemia both preceded by insulin induced hypoglycemia |
| Catecholamine response | 255 minutes | Differences in catecholamine response during hyperglycemia compared to euglycemia both preceded by insulin induced hypoglycemia |
| QTd dispersion. | 255 minutes | Difference in QT dispersion (QTd) during hyperglycemia compared to euglycemia both preceded by insulin induced hypoglycemia |
| Cortisol response | 255 minutes | Differences in cortisol responses during hyperglycemia compared to euglycemia both preceded by insulin induced hypoglycemia |
| Haemodynamic regulation. | 255 minutes | Differences in haemodynamic regulation (measured by echocardiography) during hyperglycemia compared to euglycemia both preceded by insulin-induced hypoglycemia |
| Inflammatory response | 255 minutes | Differences in markers of inflammation (high-sensitive C-reactive peptide (hs-CRP) and interleukin 6 (IL-6)) during hyperglycemia compared to euglycemia both preceded by insulin-induced hypoglycemia |
| Oxidative stress markers (8-iso-PGF2α) | 255 minutes | Differences in markers of oxidative stress (8-iso prostaglandin F2α (8-iso-PGF2α)) during hyperglycemia compared to euglycemia both preceded by insulin-induced hypoglycemia |
| Oxidative stress markers (8-oxoGuo) | 255 minutes | Differences in markers of oxidative stress (8-oxo-7,8-dihydroguanosine (8-oxoGuo)) during hyperglycemia compared to euglycemia both preceded by insulin-induced hypoglycemia |
| Growth hormone response | 255 minutes | Differences in growth hormone response during hyperglycemia compared to euglycemia both preceded by insulin induced hypoglycemia |
Countries
Denmark
Outcome results
None listed